The Food and Drug Administration approved its Optune Pax product, which delivers tumor treating fields, for certain ...

The FDA gave the go-ahead to Novocure for its tumor-treating electric fields device that targets advanced pancreatic cancer ...

Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.

The sentiment is ecstatic regarding this de-risking event. Will the stock maintain these gains, or is this a typical 'sell ...

The Swiss biopharmaceutical company’s shares surged in after-hours trading after it said the FDA approved its Optune Pax ...

As of Thursday, February 12, NovoCure Limited’s NVCR share price has surged by 28.67%, which has investors questioning if ...

NovoCure (NVCR) is back in focus after the U.S. Food and Drug Administration approved its Optune Pax device for adult patients with locally advanced pancreatic cancer, following positive Phase 3 ...

Optune Pax® with the chemotherapy combination of gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer.

NovoCure (NVCR) stock dips as Medicare revokes its billing privileges, risking ~$13M monthly revenue. Read more here.

The FDA approved Optune Pax (Novocure), a first-in-class portable device that delivers tumor-treating fields (TTFields) to ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax (R) for the treatment of adult patients with locally advanced pancreatic cancer concomitant ...

Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer cells to thwart their survival and division.